NCT06983028

Atacicept in Multiple Glomerular Diseases

A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Vera Therapeutics, Inc. · Industry
• Sex: All
• Age: 10 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and tolerability of atacicept in adult and adolescent participants and to measure the effect in reducing proteinuria and preserving renal function.

Detailed description

The study will assess the safety and efficacy of atacicept in multiple autoimmune glomerular diseases including IgAN (IgA Nephropathy), pMN (Primary Membranous Nephropathy) and MCD/FSGS (Minimal Change Disease/Focal Segmental Glomerulosclerosis) in participants ages 10 and above with weekly SC injections.

Conditions

• pMN
• IgAN
• Nephrotic Syndrome
• MCD
• FSGS

Interventions

Type	Name	Description
DRUG	Atacicept	Atacicept 150 mg SC QW via pre-filled syringe

Timeline

• Start date: 2025-07-07
• Primary completion: 2027-11-01
• Completion: 2027-11-01
• First posted: 2025-05-21
• Last updated: 2026-01-20

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study